---
title: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver
  Fibrosis
date: '2024-06-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38856224/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240611180944&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this phase 2 trial involving participants with MASH
  and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more
  effective than placebo with respect to resolution of MASH without worsening of fibrosis.
  Larger and longer trials are needed to further assess the efficacy and safety of
  tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, ...